206 related articles for article (PubMed ID: 23364629)
1. Double treatment with paricalcitol-associated calcifediol and cardiovascular risk biomarkers in haemodialysis.
Piñera-Haces C; Izquierdo-Ortiz MJ; Martín-de Francisco ÁL; García-Unzueta MT; López-Hoyos M; Toyos C; Allende N; Quintela E; Arias M
Nefrologia; 2013 Jan; 33(1):77-84. PubMed ID: 23364629
[TBL] [Abstract][Full Text] [Related]
2. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
3. Paricalcitol- or cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: results of the IMPACT-SHPT study.
Cozzolino M; Ketteler M; Martin KJ; Sharma A; Goldsmith D; Khan S
Nephrol Dial Transplant; 2014 Apr; 29(4):899-905. PubMed ID: 24500308
[TBL] [Abstract][Full Text] [Related]
4. Effect of paricalcitol on mineral bone metabolism in kidney transplant recipients with secondary hyperparathyroidism.
Borrego Utiel FJ; Bravo Soto JA; Merino Pérez MJ; González Carmelo I; López Jiménez V; García Álvarez T; Acosta Martínez Y; Mazuecos Blanca MA
Nefrologia; 2015; 35(4):363-73. PubMed ID: 26306956
[TBL] [Abstract][Full Text] [Related]
5. Daily oral 25-hydroxycholecalciferol supplementation for vitamin D deficiency in haemodialysis patients: effects on mineral metabolism and bone markers.
Jean G; Terrat JC; Vanel T; Hurot JM; Lorriaux C; Mayor B; Chazot C
Nephrol Dial Transplant; 2008 Nov; 23(11):3670-6. PubMed ID: 18579534
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of very high doses of doxercalciferol and paricalcitol on serum phosphorus in hemodialysis patients.
Joist HE; Ahya SN; Giles K; Norwood K; Slatopolsky E; Coyne DW
Clin Nephrol; 2006 May; 65(5):335-41. PubMed ID: 16724654
[TBL] [Abstract][Full Text] [Related]
7. The cost-effectiveness of extended-release calcifediol versus paricalcitol for the treatment of secondary hyperparathyroidism in stage 3-4 CKD.
Kalantar-Zadeh K; Hollenbeak CS; Arguello R; Snyder S; Ashfaq A
J Med Econ; 2020 Mar; 23(3):308-315. PubMed ID: 31726882
[No Abstract] [Full Text] [Related]
8. Effect of paricalcitol on circulating parathyroid hormone in X-linked hypophosphatemia: a randomized, double-blind, placebo-controlled study.
Carpenter TO; Olear EA; Zhang JH; Ellis BK; Simpson CA; Cheng D; Gundberg CM; Insogna KL
J Clin Endocrinol Metab; 2014 Sep; 99(9):3103-11. PubMed ID: 25029424
[TBL] [Abstract][Full Text] [Related]
9. Achievement of recommended treatment targets for bone and mineral metabolism in haemodialysis patients using paricalcitol: an observational study.
Fernström A; Giæver J; Granroth B; Hylander B; Jensen G; Christensson A; Wikström B; Weiss L; Wrege U; Jacobson SH
Scand J Urol Nephrol; 2011 Apr; 45(3):196-205. PubMed ID: 21366390
[TBL] [Abstract][Full Text] [Related]
10. Treatment of secondary hyperparathyroidism with paricalcitol in patients with end-stage renal disease undergoing hemodialysis in Turkey: an observational study.
Koc H; Hoser H; Akdag Y; Kendir C; Ersoy FF
Int Urol Nephrol; 2019 Jul; 51(7):1261-1270. PubMed ID: 31161518
[TBL] [Abstract][Full Text] [Related]
11. Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters.
Matias PJ; Jorge C; Ferreira C; Borges M; Aires I; Amaral T; Gil C; Cortez J; Ferreira A
Clin J Am Soc Nephrol; 2010 May; 5(5):905-11. PubMed ID: 20203163
[TBL] [Abstract][Full Text] [Related]
12. Evidence for persistent vitamin D 1-alpha-hydroxylation in hemodialysis patients: evolution of serum 1,25-dihydroxycholecalciferol after 6 months of 25-hydroxycholecalciferol treatment.
Jean G; Terrat JC; Vanel T; Hurot JM; Lorriaux C; Mayor B; Chazot C
Nephron Clin Pract; 2008; 110(1):c58-65. PubMed ID: 18724068
[TBL] [Abstract][Full Text] [Related]
13. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM
Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251
[TBL] [Abstract][Full Text] [Related]
14. Paricalcitol reduces proteinuria but does not modify peritoneal protein loss in patients on peritoneal dialysis.
Sánchez-Álvarez JE; Rodríguez-Suárez C; Coronel-Aguilar D; González-Díaz I; Núñez-Moral M; Peláez-Requejo B; Fernández-Viña A; Quintana-Fernández A
Nefrologia; 2013 Jan; 33(1):70-6. PubMed ID: 23364628
[TBL] [Abstract][Full Text] [Related]
15. Beneficial effects of selective vitamin D receptor activation by paricalcitol in chronic kidney disease.
Donate-Correa J; Domínguez-Pimentel V; Muros-de-Fuentes M; Mora-Fernández C; Martín-Núñez E; Cazaña-Pérez V; Navarro-González JF
Curr Drug Targets; 2014; 15(7):703-9. PubMed ID: 24745821
[TBL] [Abstract][Full Text] [Related]
16. Paricalcitol regulatory effect on inflammatory, fibrotic and anticalcificating parameters in renal patiente. Far beyond mineral bone disease regulation.
Salanova Villanueva L; Gil Giraldo Y; Santos Sánchez-Rey B; Aguilera Peralta A
Nefrologia (Engl Ed); 2020; 40(2):171-179. PubMed ID: 31740151
[TBL] [Abstract][Full Text] [Related]
17. Pathogenesis and treatment of secondary hyperparathyroidism in dialysis patients: the role of paricalcitol.
Cozzolino M; Galassi A; Gallieni M; Brancaccio D
Curr Vasc Pharmacol; 2008 Apr; 6(2):148-53. PubMed ID: 18393917
[TBL] [Abstract][Full Text] [Related]
18. [Cholecalciferol supplementation improves secondary hyperparathyroidism control in hemodialysis patients].
Massimetti C; Bellasi A; Feriozzi S
G Ital Nefrol; 2020 Jun; 37(3):. PubMed ID: 32530156
[No Abstract] [Full Text] [Related]
19. Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis.
Greenbaum LA; Benador N; Goldstein SL; Paredes A; Melnick JZ; Mattingly S; Amdahl M; Williams LA; Salusky IB
Am J Kidney Dis; 2007 Jun; 49(6):814-23. PubMed ID: 17533024
[TBL] [Abstract][Full Text] [Related]
20. Rationale for Raising Current Clinical Practice Guideline Target for Serum 25-Hydroxyvitamin D in Chronic Kidney Disease.
Strugnell SA; Sprague SM; Ashfaq A; Petkovich M; Bishop CW
Am J Nephrol; 2019; 49(4):284-293. PubMed ID: 30878999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]